UA86350C2 - Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10 - Google Patents

Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10

Info

Publication number
UA86350C2
UA86350C2 UAA200500986A UA2005000986A UA86350C2 UA 86350 C2 UA86350 C2 UA 86350C2 UA A200500986 A UAA200500986 A UA A200500986A UA 2005000986 A UA2005000986 A UA 2005000986A UA 86350 C2 UA86350 C2 UA 86350C2
Authority
UA
Ukraine
Prior art keywords
polypeptide
heading
zcyto10
antibody
expression vector
Prior art date
Application number
UAA200500986A
Other languages
English (en)
Ukrainian (uk)
Inventor
Деррел К. Конклин
Бетти А. Хелдмен
Анжелика Гросман
Original Assignee
Займодженетикс, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Займодженетикс, Инк filed Critical Займодженетикс, Инк
Publication of UA86350C2 publication Critical patent/UA86350C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)

Abstract

Изобретение относится к цитокиноподобным полипептидам млекопитающих Zcyto10 и их применению для изготовления лекарства для усиления заживления ран, для борьбы с микробными или вирусными инфекциями, для предупреждения и лечения тромбоцитопении, обусловленной химиотерапией или радиационной терапией у больных раком. Заявлен экспресионный вектор, который включает цитокиноподобный полипептид млекопитающих Zcyto10, культивированную эвкариотную или прокариотную клетку, в которую введен данный вектор, антитела, которые специфично связывают упомянутый полипептид, и антиидиотипические антитела, которые связывают антитела.
UAA200500986A 1997-11-26 1998-11-25 Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10 UA86350C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26

Publications (1)

Publication Number Publication Date
UA86350C2 true UA86350C2 (en) 2009-04-27

Family

ID=25526742

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200500986A UA86350C2 (en) 1997-11-26 1998-11-25 Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10
UA2000063693A UA73275C2 (en) 1997-11-26 1998-11-25 A mammalian cytokine-like polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA2000063693A UA73275C2 (en) 1997-11-26 1998-11-25 A mammalian cytokine-like polypeptide

Country Status (20)

Country Link
EP (3) EP1719780A3 (ru)
JP (2) JP5191619B2 (ru)
KR (1) KR100574387B1 (ru)
CN (2) CN1618969A (ru)
AT (1) ATE269902T1 (ru)
AU (1) AU739420B2 (ru)
BR (1) BR9814904A (ru)
CA (1) CA2312000C (ru)
CZ (1) CZ300849B6 (ru)
DE (1) DE69824755T2 (ru)
DK (1) DK1032671T3 (ru)
EA (2) EA010741B1 (ru)
ES (1) ES2218872T3 (ru)
HU (1) HU227703B1 (ru)
IL (2) IL136076A0 (ru)
NO (2) NO326561B1 (ru)
NZ (1) NZ504751A (ru)
PL (2) PL198687B1 (ru)
UA (2) UA86350C2 (ru)
WO (1) WO1999027103A1 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
DE60040240D1 (de) 1999-12-23 2008-10-23 Zymogenetics Inc Löslicher interleukin-20 rezeptor
DK1616575T3 (da) 1999-12-23 2012-09-10 Zymogenetics Inc Fremgangsmåde til behandling af inflammation
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
WO2002012345A2 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
ES2267814T3 (es) 2000-09-15 2007-03-16 Zymogenetics, Inc. Metodo para tratar la inflamacion.
US20030032167A1 (en) * 2000-10-20 2003-02-13 Conklin Darrell C. Secreted alpha-helical protein zlmda24
EP1390060A2 (en) * 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
US7101539B2 (en) 2001-02-28 2006-09-05 Eli Lilly And Company Use of LP82 to treat hematopoietic disorders
EP1439850A4 (en) * 2001-10-22 2006-05-03 Lilly Co Eli SOLUBLE PROTEINS THAT RESIST CYTOKIN SIGNAL TRANSFER PATHS
JP4532902B2 (ja) 2001-12-17 2010-08-25 ザイモジェネティクス，インコーポレイティド 子宮頸部癌の治療方法
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
EP1653995A1 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
CA2542546A1 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2005059127A1 (en) 2003-12-19 2005-06-30 Novo Nordisk A/S Processing of peptides and proteins
EP2842576B1 (en) 2004-01-21 2017-06-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
CA2558811A1 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
DE602005022475D1 (de) 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
EP2192132A3 (en) 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
JP5592357B2 (ja) 2008-05-27 2014-09-17 ダコ・デンマーク・エー／エス 新規なハイブリダイゼーションバッファーを用いた染色体異常の検出のための組成物及び方法
US8287861B2 (en) 2008-06-30 2012-10-16 Novo Nordisk A/S Anti-human interleukin-20 antibodies
WO2010042634A1 (en) * 2008-10-07 2010-04-15 National Cheng Kung University Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis
US9388456B2 (en) 2009-02-26 2016-07-12 Dako Denmark A/S Compositions and methods for performing a stringent wash step in hybridization applications
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
JP5976849B2 (ja) * 2012-03-05 2016-08-24 シージーン アイエヌシー ＰＴＯ切断及び伸長アッセイによるターゲット核酸配列でのヌクレオチド変異検出｛ＤｅｔｅｃｔｉｏｎｏｆＮｕｃｌｅｏｔｉｄｅＶａｒｉａｔｉｏｎｏｎＴａｒｇｅｔＮｕｃｌｅｉｃＡｃｉｄＳｅｑｕｅｎｃｅｂｙＰＴＯＣｌｅａｖａｇｅａｎｄＥｘｔｅｎｓｉｏｎＡｓｓａｙ｝
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
EP3464357A1 (en) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0963377T3 (da) * 1996-08-30 2009-05-18 Human Genome Sciences Inc Interleukin-19
DK1616575T3 (da) * 1999-12-23 2012-09-10 Zymogenetics Inc Fremgangsmåde til behandling af inflammation

Also Published As

Publication number Publication date
IL136076A (en) 2007-12-03
EP1424393A2 (en) 2004-06-02
EP1719780A3 (en) 2006-12-20
NO326561B1 (no) 2009-01-12
ATE269902T1 (de) 2004-07-15
EA005581B1 (ru) 2005-04-28
EP1719780A2 (en) 2006-11-08
AU739420B2 (en) 2001-10-11
EP1032671B1 (en) 2004-06-23
NO20002698D0 (no) 2000-05-26
ES2218872T3 (es) 2004-11-16
JP5331054B2 (ja) 2013-10-30
JP5191619B2 (ja) 2013-05-08
NZ504751A (en) 2001-10-26
KR100574387B1 (ko) 2006-04-27
DE69824755D1 (de) 2004-07-29
UA73275C2 (en) 2005-07-15
AU1607799A (en) 1999-06-15
DK1032671T3 (da) 2004-10-11
CN1618969A (zh) 2005-05-25
IL136076A0 (en) 2001-05-20
EA200401501A1 (ru) 2006-02-24
NO20002698L (no) 2000-07-20
EA010741B1 (ru) 2008-10-30
HU227703B1 (en) 2011-12-28
CN1282372A (zh) 2001-01-31
PL198687B1 (pl) 2008-07-31
CA2312000C (en) 2013-03-26
NO329731B1 (no) 2010-12-13
CN1247780C (zh) 2006-03-29
CZ20001910A3 (cs) 2000-11-15
EP1032671A1 (en) 2000-09-06
DE69824755T2 (de) 2005-08-04
NO20074516L (no) 2000-07-20
WO1999027103A1 (en) 1999-06-03
PL195304B1 (pl) 2007-08-31
JP2001524313A (ja) 2001-12-04
HUP0100436A2 (hu) 2001-06-28
HUP0100436A3 (en) 2003-08-28
CZ300849B6 (cs) 2009-08-26
EP1424393A3 (en) 2004-06-09
BR9814904A (pt) 2000-10-03
CA2312000A1 (en) 1999-06-03
KR20010032490A (ko) 2001-04-25
JP2010187698A (ja) 2010-09-02
PL340755A1 (en) 2001-02-26
EA200000565A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
UA86350C2 (en) Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
YU54202A (sh) Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
GR3034349T3 (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
BR9713755A (pt) Proteìna, proteìna de fusão, sequência de ácido nucleico, vetor, célula hospedeira procariótica ou eucariótica, processo para produzir uma proteìna, composição farmacêutica, e processo de tratamento de um distúrbio.
EP1135477A4 (en) HUMANIZED MONOCLONAL ANTIBODIES
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
UA102988C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕН-СВЯЗЫВАЮЩАЯ ЧАСТЬ, КОТОРАЯ СВЯЗЫВАЕТ TNFα ЧЕЛОВЕКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, В КОТОРОМ АКТИВНОСТЬ TNFα ЯВЛЯЕТСЯ ВРЕДНОЙ
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
MX9705039A (es) Genes y proteinas de muerte celular programada.
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
GB8805792D0 (en) Medicaments
MXPA02008239A (es) Gen humano de la esquizofrenia.
HK1039622A1 (en) Lantibiotic
PT1042492E (pt) Anticorpos monoclonais humanizados que protegem contra doença induzida pela toxina shiga
AU5103996A (en) Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
WO1997004104A3 (en) Tumor type ii hexokinase transcription regulatory regions
CA2151381A1 (fr) Lipase gastrique du chien recombinante et compositions pharmaceutiques